Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2022 | An insight into how bispecifics are changing the lymphoma treatment landscape

Ulrich Jäger • 10 Jun 2022
EHA 2022
Lymphoma Antibodies CAR-T Epcoritamab Glofitamab

Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, shares some insights into how bispecifics are changing the lymphoma treatment landscape, highlighting the promise of agents including epcoritamab and glofitamab. Prof. Jäger also discusses the promising results observed in clinical trials and the importance of investigating the long-term use of these agents. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

More from Ulrich Jäger

2:33
The effect of lymphodepleting agents on rate and severity of toxicities following CAR-T infusion
Ulrich Jäger • 16 Feb 2024
1:20
The importance of lymphodepletion, an undervalued component of the CAR-T therapy cycle
Ulrich Jäger • 16 Feb 2024
3:31
The role of lymphodepletion in CAR T-cell therapy: current knowledge & the need for personalization
Ulrich Jäger • 16 Feb 2024
0:58
CAR-T therapy in non-Hodgkin lymphoma: current status and future outlooks
Ulrich Jäger • 10 Feb 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals